Where is Interdict located?

Interdict is headquartered in San Francisco, United States.

How many employees does Interdict have?

As of Aug 31, 2026, the latest employee count at Interdict is 7.

Where does Interdict rank among its competitors?

Interdict ranks 2439th amongst 3389 active competitors, of which 1127 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Interdict?

Interdict's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Interdict - 2026 Company Profile, Funding & Competitors

Company Details

Developer of small molecule drugs inhibiting protein synthesis in cells. These molecules interact with the nascent polypeptide to prevent the production of pathogenic proteins. The focus remains on addressing targets associated with oncology and neurodegenerative diseases through ribosomal inhibition.

Website: www.interdictbio.com/
Email ID: *****@interdictbio.com

Key Metrics

Location

San Francisco, United States

Stage

Funding Raised

Investors

Venrock & 1 more

Ranked

2439^th among 3389 active competitors

Employee Count

7 as on Aug 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3013 more

View Interdict's full profile

Interdict is a funded company. Interdict has 2 institutional investors.

View details of Interdict's funding rounds and investors

Interdict's employee count trend

Interdict has 7 employees as of Aug 26. Here is Interdict's employee count trend over the years:

Uncover Interdict's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Interdict include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Interdict, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Leaps by Bayer, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
2439th	Interdict San Francisco (United States), Funding Raised	Developer of small molecule drugs inhibiting protein synthesis in cells	-	Venrock, Altitude Life Science Ventures	24/100